VLPM01
/ VLP Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 08, 2021
To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers
(clinicaltrials.gov)
- P1; N=36; Completed; Sponsor: VLP Therapeutics; Recruiting ➔ Completed
Trial completion • Infectious Disease • Malaria
1 to 1
Of
1
Go to page
1